RE: RNS6 Sep 2022 08:56
Sara Barrington, CEO, Verici Dx, said: " This new validating data demonstrates that Clarava ™ can have a significant impact for transplant clinicians understanding of which patients could experience early acute rejection, pre-surgery. As a result, clinicians can make better decisions in advance that can help drive better outcomes post-transplant."
The extension of the validation study has no material impact on the Company's cash resources and runway, as the Clarava™ validation work is leveraging the ongoing, budgeted clinical validation study for Verici Dx's third product, Protega ™, as each patient's sample can be used for multiple tests. Further updates on the Company's progress will be provided shortly in its interim results announcement, which is due to be released on 7 September 2022.
GL.